Novel Methods of Targeting IL-1 Signalling for the Treatment of Breast Cancer Bone Metastasis
Breast cancer bone metastasis is currently incurable. Evidence suggests that inhibiting IL-1 signalling with the IL1R antagonist, Anakinra, or the IL1β antibody, Canakinumab, prevents metastasis and almost eliminates breast cancer growth in the bone. However, these drugs increase primary tumour grow...
Main Authors: | Jiabao Zhou, Jennifer M. Down, Christopher N. George, Jessica Murphy, Diane V. Lefley, Claudia Tulotta, Marwa A. Alsharif, Michael Leach, Penelope D. Ottewell |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/19/4816 |
Similar Items
-
IL4/IL4R signaling promotes the osteolysis in metastatic bone of CRC through regulating the proliferation of osteoclast precursors
by: Qian Jin, et al.
Published: (2021-12-01) -
Prognosis value of IL-6, IL-8, and IL-1β in serum of patients with lung cancer: A fresh look at interleukins as a biomarker
by: Xi Yan, et al.
Published: (2022-08-01) -
Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases
by: Paola Maroni, et al.
Published: (2021-06-01) -
Modeling Spontaneous Bone Metastasis Formation of Solid Human Tumor Xenografts in Mice
by: Vera Labitzky, et al.
Published: (2020-02-01) -
microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11
by: Wei-Luo Cai, et al.
Published: (2018-01-01)